TABLE 3.
Treatment effectiveness among trial participants randomly assigned to standard or sequential therapy, stratified according to Helicobacter pylori antimicrobial susceptibility status
| Antimicrobial susceptibility | Assigned treatment, n | Tested post-treatment, n | Negative post-treatment status, n | Treatment effectiveness, % (95% CI) | |
|---|---|---|---|---|---|
|
| |||||
| Intention to treat | Per protocol | ||||
| Standard therapy (PPI-CA) | 53 | 49 | 29 | 55 (40–68) | 59 (45–73) |
| Metronidazole resistant | 7 | 7 | 4 | † | † |
| Susceptible* | 20 | 17 | 8 | 40 (19–64) | 47 (23–72) |
| Susceptibility unknown | 26 | 25 | 17 | 65 (44–83) | 68 (46–85) |
| Sequential therapy | 51 | 40 | 28 | 55 (40–69) | 70 (53–83) |
| Metronidazole resistant | 7 | 4 | 4 | † | † |
| Clarithromycin resistant | 1 | 1 | 0 | † | † |
| Metronidazole and clarithromycin resistant | 1 | 1 | 1 | † | † |
| Susceptible* | 13 | 13 | 9 | 69 (39–91) | 69 (39–91) |
| Susceptibility unknown | 29 | 21 | 14 | 48 (29–67) | 74 (49–91) |
*
Susceptible to amoxicillin, clarithromycin and metronidazole;
†
Estimates not reported for subgroups with fewer than 10 observations. PPI-CA Proton pump inhibitor-clarithromycin and amoxicillin